<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38673">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133222</url>
  </required_header>
  <id_info>
    <org_study_id>13-AOI-04</org_study_id>
    <nct_id>NCT02133222</nct_id>
  </id_info>
  <brief_title>Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy</brief_title>
  <acronym>AMMAM</acronym>
  <official_title>Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapies that target specific molecules markedly inhibit cancer growth in several
      malignancies, and provide valuable strategies for the treatment of advanced melanoma. In
      recent years, BRAF and KIT have become established therapeutic targets in melanoma patients
      showing activating mutations in these oncogenes. However, it is crucial that genetic
      mutations present in the melanoma lesions are identified if the investigators are to design
      tailormade therapies for individual patients. The tumour genotypes that determine the
      selection of molecular-targeted therapies are usually identified in primary tumours;
      however, primary tumours are not always representative of metastases. Circulating free DNA
      may be a source of valuable information because it can be obtained via routine blood
      sampling, it provides real-time information about a patient's current disease state, and it
      allows monitoring and molecular characterization before and after chemotherapy. The aim of
      the study is to determine the mutational status in circulating DNA in melanoma metastatic
      patients, with the Sequenom Mass Array, a next generation sequencing technology. Results
      obtained before and after treatment will be compared with the primary tumor genotype.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Response to treatment (MRI, Scanner)</measure>
    <time_frame>at three months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison between first day and third months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic (Stage IV) Melanoma</condition>
  <arm_group>
    <arm_group_label>Metastatic (stage IV) melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <arm_group_label>Metastatic (stage IV) melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years

          -  Surgical biopsy for histologic diagnostic

          -  All melanoma subtypes

          -  Known genotype BRAF V600

          -  Affiliation social security

          -  Consent form signed

        Exclusion Criteria:

          -  Patient with histories of cancer or the other synchronous cancer

          -  Pregnant women

          -  Breast-feeding women

          -  Vulnerable patients: major under guardianship; patient deprived of its rights
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elodie LONG-MIRA, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elodie LONG-MIRA, PH</last_name>
    <email>long.e@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanina OLIVERI, CRA</last_name>
    <phone>00 33 4 92 03 42 54</phone>
    <email>oliveri.v@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanina OLIVERI, CRA</last_name>
      <phone>0033 4 92 03 42 54</phone>
      <email>oliveri.v@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Paul HOFMAN, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie LONG-MIRA, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe BAHADORAN, PU6PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Philippe LACOUR, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri MONTAUDIE, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
